Danish Pharmacovigilance Update, February 2016
09 March 2016
News from the EU
- SGLT2 (sodium-glucose co-transporter 2) inhibitors and development of life-threatening atypical ketoacidosis in patients with type 2 diabetes, page 2
- New recommendations to minimise the risk of PML in connection with treatment with natalizumab (Tysabri), page 3
- EU's list of recommendations on safety signals, page 4
News from the Danish Medicines Agency
- Special focus on reported adverse reactions to biological medicines and biosimilars, page 5
- Development in the number of melatonin users younger than 25 years of age from 2007-2015, page 12
- Beware of interactions between miconazole and warfarin – new, serious ADR reports, page 14
Short news
- Most recent Direct Healthcare Professional Communications (DHPCs), page 15